Hand sanitiser company Byotrol (BYOT:AIM) said it has seen a very substantial spike in demand for its range of infection protection products over the last seven weeks. Consequently, its full-year results for the period ended 31 March are expected to exceed guidance given at the interim stage. The shares shot up 42% to 5.1p.
At the interim stage the company was guiding for positive earnings before interest, tax, depreciation and amortisation (EBITDA). The out-turn will depend on how many orders it can complete before the cut-off on 31 March.
Confirmed orders to the end of June are currently £1.7m with many more still to be processed and compares with an historical order book of £0.35m.
Chief executive David Traynor commented, ‘the Byotrol team is working very hard with customers and suppliers to meet the huge demand for our excellent infection control products. We are currently selling everything we can make, and are investigating every opportunity to increase capacity further.’
UNIQUE COMBINATION
Separately the company announced a collaboration with fellow infection prevention firm Tristel (TSTL:AIM), where it will combine its long lasting anti-microbial technology with Tristel’s proprietary sporicidal chemistry.
The unique product will speedily eliminate spores on application, (less than two minutes) and will then remain active against microbes for an 8-hour period after application.
The agreement is for 10 years and has exclusivity in hospitals across the UK, while other territories are non-exclusive. Tristel will pay the company a combination of fees based on supplying products, and royalties, based on success, with meaningful minimum guarantee payments.
